Incyte (NASDAQ:INCY) Insider Thomas Tray Sells 610 Shares of Company Stock

Incyte Corporation (NASDAQ:INCY) insider Thomas Tray sold 610 shares of the company’s stock in a transaction on Tuesday, November 3rd. The stock was sold at an average price of $118.96, for a total transaction of $72,565.60. Following the sale, the insider directly owned 21,126 shares of the company’s stock, valued at approximately $2,513,148.96. This trade represents a 2.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Incyte Trading Down 3.9%

Shares of NASDAQ INCY opened at $118.01 on Friday. The stock has a fifty day moving average price of $119.78 and a 200 day moving average price of $108.42. Incyte Corporation has a 12-month low of $89.25 and a 12-month high of $132.60. The company has a market cap of $24.05 billion, a P/E ratio of 57.95, a P/E/G ratio of 4.47 and a beta of 0.78.

Incyte (NASDAQ:INCY) last issued its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported ($3.60) EPS for the quarter, topping analysts’ consensus estimates of ($3.93) by $0.33. Incyte had a return on equity of 7.92% and a net margin of 6.71%. The company had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter in the previous year, the firm posted $2.26 earnings per share. The firm’s quarterly revenue was up 14.0% on a year-over-year basis. On average, sell-side analysts forecast that Incyte Corporation will post 2.24 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of INCY. Fifth Third Bancorp lifted its holdings in Incyte by 7.6% in the third quarter. Fifth Third Bancorp now owns 29,647 shares of the biopharmaceutical company’s stock worth $3,598,000 after purchasing an additional 2,090 shares during the period. Maryland State Retirement & Pension System grew its position in Incyte by 12.4% in the 3rd quarter. Maryland State Retirement & Pension System now owns 9,790 shares of the biopharmaceutical company’s stock valued at $1,188,000 after buying an additional 1,081 shares in the last quarter. Ritholtz Wealth Management increased its stake in Incyte by 97.5% during the 3rd quarter. Ritholtz Wealth Management now owns 19,195 shares of the biopharmaceutical company’s stock valued at $2,329,000 after buying an additional 9,475 shares during the period. Lido Advisors LLC increased its stake in Incyte by 1.2% during the 3rd quarter. Lido Advisors LLC now owns 18,556 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 229 shares during the period. Finally, Keybank National Association OH raised its position in shares of Incyte by 6.9% during the 3rd quarter. Keybank National Association OH now owns 2,626 shares of the biopharmaceutical company’s stock worth $319,000 after buying an additional 169 shares in the last quarter. Institutional investors and hedge funds own 96.97% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the company. HC Wainwright restated a “buy” rating on shares of Incyte in a report on Tuesday, October 27th. JPMorgan Chase & Co. increased their price objective on shares of Incyte from $120.00 to $123.00 and gave the company a “neutral” rating in a research report on Monday, September 28th. Cantor Fitzgerald reiterated a “neutral” rating on shares of Incyte in a research note on Friday, September 11th. BMO Capital Markets reissued a “market perform” rating on shares of Incyte in a research report on Tuesday, October 27th. Finally, Zacks Research downgraded shares of Incyte from a “hold” rating to a “strong sell” rating in a research note on Wednesday, October 14th. Twelve equities research analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $132.86.

Incyte News Summary

Here are the key news stories impacting Incyte this week:

• Positive Sentiment: Canaccord Genuity maintained its Buy rating and $152 price target, citing upcoming ASH 2026 data for ’989 as supportive of its view. Article
• Positive Sentiment: Incyte plans to present new data across its hematology portfolio at ASH 2026. The results could provide investors with updates on its pipeline and future growth prospects. Article
• Neutral Sentiment: Incyte sued a generic drug manufacturer over patents for a blood-cancer treatment. Protecting patent rights could help defend product revenue, although litigation outcomes and timing are uncertain. Article
• Neutral Sentiment: Insider Thomas Tray sold 610 shares under a pre-arranged Rule 10b5-1 plan, a small portion of his holdings. The planned sale may be less informative than an unplanned transaction. SEC filing
• Negative Sentiment: Leerink Partners lowered its price target to $150 from $154, though it kept an Outperform rating—still signaling substantial potential upside from the cited share price. Article

Incyte Company Profile

Incyte Corporation is a biopharmaceutical company that discovers, develops and commercializes medicines for oncology and inflammatory or autoimmune diseases. The company focuses on therapies that target specific biological pathways, including Janus kinase (JAK), fibroblast growth factor receptor (FGFR) and other mechanisms involved in cancer and immune-related conditions.

Its key products include Jakafi (ruxolitinib), a JAK inhibitor used in the United States for certain blood cancers and graft-versus-host disease; Opzelura (ruxolitinib cream), a topical treatment for atopic dermatitis and nonsegmental vitiligo; and Pemazyre (pemigatinib), an FGFR inhibitor approved for selected patients with cholangiocarcinoma and certain myeloid or lymphoid neoplasms.